Decoy Therapeutics Stock (NASDAQ:DCOY)


OwnershipFinancialsChart

Previous Close

$5.91

52W Range

$4.32 - $415.80

50D Avg

$6.36

200D Avg

$14.48

Market Cap

$3.11M

Avg Vol (3M)

$232.17K

Beta

0.59

Div Yield

-

DCOY Company Profile


Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

11

IPO Date

Jan 29, 2015

Website

DCOY Performance


DCOY Financial Summary


Dec 25Dec 24Dec 23
Revenue---
Operating Income$-12.61M$-5.73M$-12.89M
Net Income$-12.52M$-5.58M$-12.54M
EBITDA$-12.61M$-5.73M$-12.88M
Basic EPS$-129.10$-86.85$-0.06
Diluted EPS$-129.10$-86.85$-0.06

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q2 22Aug 08, 22 | 11:00 AM
Q1 22May 12, 22 | 5:00 PM
Q4 21Mar 10, 22 | 5:00 PM

Peer Comparison


TickerCompany
PBMPsyence Biomedical Ltd.
SPRCSciSparc Ltd.
GTBPGT Biopharma, Inc.
SLXNSilexion Therapeutics Ltd.
REVBRevelation Biosciences, Inc.
INDPIndaptus Therapeutics, Inc.
ENVBEnveric Biosciences, Inc.